LLY

1,026.28

+0.23%↑

JNJ

199.72

+1.89%↑

ABBV

234.15

+0.77%↑

UNH

324.65

+1.02%↑

AZN

89.87

+0.82%↑

LLY

1,026.28

+0.23%↑

JNJ

199.72

+1.89%↑

ABBV

234.15

+0.77%↑

UNH

324.65

+1.02%↑

AZN

89.87

+0.82%↑

LLY

1,026.28

+0.23%↑

JNJ

199.72

+1.89%↑

ABBV

234.15

+0.77%↑

UNH

324.65

+1.02%↑

AZN

89.87

+0.82%↑

LLY

1,026.28

+0.23%↑

JNJ

199.72

+1.89%↑

ABBV

234.15

+0.77%↑

UNH

324.65

+1.02%↑

AZN

89.87

+0.82%↑

LLY

1,026.28

+0.23%↑

JNJ

199.72

+1.89%↑

ABBV

234.15

+0.77%↑

UNH

324.65

+1.02%↑

AZN

89.87

+0.82%↑

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Open

SectorHealthcare

20.8 -4.15

Buy Sell

Overview

Share price change

24h

Current

Min

20.78

Max

21.7

Key metrics
By Trading Economics
Income	4.8M -36M
Sales	6.1M 116M
Profit margin	-30.977
Employees	1,869
EBITDA	10M -45M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+147.03% upside

Market Stats
By TradingEconomics
Market Cap	-552M 2.5B
Previous open	24.95
Previous close	20.8

News Sentiment

By Acuity

31%

69%

69 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 lis 2025, 17:45 UTC

Earnings

Major Market Movers

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 lis 2025, 17:31 UTC

Earnings

Major Market Movers

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

16 lis 2025, 23:40 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

16 lis 2025, 23:36 UTC

Market Talk

Nikkei May Edge Lower Amid Lingering Worries Over Elevated Tech Valuations -- Market Talk

16 lis 2025, 23:26 UTC

Market Talk

RBA Policy Meetings May Contain a Trap for Traders -- Market Talk

16 lis 2025, 16:20 UTC

Earnings

Fed Minutes, Plus Walmart, Target, Home Depot, Nvidia, and More Stocks to Watch This Week -- Barrons.com

15 lis 2025, 09:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

15 lis 2025, 09:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

15 lis 2025, 00:08 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 lis 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 lis 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 lis 2025, 22:35 UTC

Earnings

Acquisitions, Mergers, Takeovers

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 lis 2025, 22:32 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 lis 2025, 22:29 UTC

Earnings

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 lis 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 lis 2025, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

14 lis 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 lis 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 lis 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 lis 2025, 20:17 UTC

Acquisitions, Mergers, Takeovers

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 lis 2025, 19:29 UTC

Market Talk

Earnings

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 lis 2025, 18:44 UTC

Market Talk

Earnings

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 lis 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14 lis 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 lis 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 lis 2025, 17:20 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

14 lis 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

14 lis 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 lis 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14 lis 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

147.03% upside

12 Months Forecast

Average 53.73 USD 147.03%

High 74 USD

Low 25.7 USD

Based on 7 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

69 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.